Part 2 – Medicaid Rebate Challenges: Delving Deeper into the Knotty Issues

April 29, 2014 10:15am

William A. Sarraille
Partner
Sidley Austin LLP

T. Reed Stephens
Partner
McDermott Will & Emery LLP

• How does the new AMP definition affect AMP calculations?
– Calculating AMP for products that are not sold to community retail pharmacies
• The 5(i) alternative calculation
• Rebates to managed care organizations
• Issues around the “default” rule
• Authorized generics
• Problems in bona fi de service fees: reconciling the different definitions
• How are manufacturers addressing the change in the AMP definition?
• Medicaid reimbursement provisions in health care reform
• Public availability of AMP
• Implications of the 100% cap on the URA for 340B prices
• Pricing of line extension products
• Systems confi guration and maintenance in light of health care reform